These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 17376486)
1. Adherence to interferon-beta treatment and results of therapy switching. Clerico M; Barbero P; Contessa G; Ferrero C; Durelli L J Neurol Sci; 2007 Aug; 259(1-2):104-8. PubMed ID: 17376486 [TBL] [Abstract][Full Text] [Related]
2. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Schwid SR; Panitch HS Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202 [TBL] [Abstract][Full Text] [Related]
3. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS. Durelli L J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396 [TBL] [Abstract][Full Text] [Related]
4. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Flechter S; Vardi J; Finkelstein Y; Pollak L Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394 [TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E; Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983 [TBL] [Abstract][Full Text] [Related]
6. Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing. Blumhardt LD Int J Clin Pract Suppl; 2002 Sep; (131):9-16. PubMed ID: 12564807 [TBL] [Abstract][Full Text] [Related]
7. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients. Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926 [TBL] [Abstract][Full Text] [Related]
8. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466 [TBL] [Abstract][Full Text] [Related]
9. Interferon after 10 years in patients with multiple sclerosis. Pozzilli C; Prosperini L; Sbardella E; Paolillo A Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723 [TBL] [Abstract][Full Text] [Related]
10. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872 [TBL] [Abstract][Full Text] [Related]
11. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study. Webb UH J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303 [TBL] [Abstract][Full Text] [Related]
12. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450 [TBL] [Abstract][Full Text] [Related]
13. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis. Cunningham A; Gottberg K; von Koch L; Hillert J Acta Neurol Scand; 2010 Mar; 121(3):154-60. PubMed ID: 20055771 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320 [TBL] [Abstract][Full Text] [Related]
16. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response. Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855 [TBL] [Abstract][Full Text] [Related]
17. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Comi G Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384 [TBL] [Abstract][Full Text] [Related]
18. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439 [TBL] [Abstract][Full Text] [Related]
19. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154 [TBL] [Abstract][Full Text] [Related]